Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer

Radiology

Volumn 250, Issue 3, 2009, Pages 803-812

  Shukla Dave, Amita ^a   Hricak, Hedvig ^a   Ishill, Nicole M ^a   Moskowitz, Chaya S ^a   Drobnjak, Marija ^a   Reuter, Victor E ^a   Zakian, Kristen L ^a   Scardino, Peter T ^a   Cordon Cardo, Carlos ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER; PHOSPHOTRANSFERASE; PROTEIN KINASE B;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; BIOLOGICAL MARKERS; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TISSUE DISTRIBUTION;

EID: 62649091307     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2503080473     Document Type: Article

References (58)

1. Klein EA. What is 'insignificant' prostate carcinoma? Cancer 2004;101:1923-1925.
2. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage TIC adenocarcinoma of the prostate. J Urol 1997;137:2206-2209.
3. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407.
4. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005;66:356-360.
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
6. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-1063.
7. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-1797.
8. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1443-1451.
9. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007;177:107-112.
10. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007;99:786-793.
11. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814.
12. Swans on MG, Vigneron DB, Tabatabai ZL, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003;50:944-954.
13. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005;11:7658-7663.
14. Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 2005;95:657-669.
15. Cordon-Cardo C, Kotsianti A, Verbel DA, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007;117:1876-1883.
16. de la Taille A, Buttyan R, Benson MC, Katz AE. The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy. Semin Urol Oncol 1998;16:137-144.
17. Drobnjak M, Melamed J, Taneja S, et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 2003;9:2613-2619.
18. Epstein JI. What's new in prostate cancer disease assessment in 2006? Curr Opin Urol 2006;16:146-151.
19. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribri-form acinar adenocarcinomas of the prostate. Am J Surg Pathol 2007;31:889-894.
20. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13:748-753.
21. Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003;62(suppl 1):19-35.
22. Kurek R, Nunez G, Tselis N, et al. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004;10:5808-5814.
23. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-1171.
24. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005;24:7435-7442.
25. Quinn DI, Henshall SM, Sutherland RL. Mo
26. lecuar markers of prostate cancer outcome. Eur J Cancer 2003;41:838-887.
27. Rubio J, Ramos D, Lopez-Guerrero JA, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer: prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2003;48:745-731.
28. Saidi O, Cordon-Cardo C, Costa J. Technology insight: will systems pathology replace the pathologist? Nat Clin Pract Urol 2007;4:39-45.
29. Shimizu Y, Segawa T, Inoue T, et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 2007;100:685-690.
30. Teo K, Gemmell L, Mukherjee R, Traynor P, Edwards J. Bad expression influences time to androgen escape in prostate cancer. BJU Int 2007;100:691-696.
31. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-527.
32. Trover DA, Mubiru J, Leach RJ, Naylor SL. Promise and challenge: markers of prostate cancer detection, diagnosis and prognosis. Dis Markers 2004;20:117-128.
33. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337.
34. 3) spatial resolution. Radiology 1996;198:795-805.
35. Males RG, Vigneron DB, Star-Lack J, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43:17-22.
36. Pels P, Ozturk-Isik E, Swanson MG, et al. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed 2006;19:188-197.
37. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43:60-67.
38. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;132:1714-1720.
39. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-2318.
40. Delong ER, Delong DM, Clarke-Pearson DL. Comapring the areas under two or more correlated receiver opertaing curves: a non parametric approach. Biometrics 1988;44:837-845.
41. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford, England: Oxford University Press, 2003;67-79.
42. Carroll PR, Coakley FV, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 2006;8(suppl 1):S4-S10.
43. Futterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42:116-122.
44. Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005;78(suppl 2):S103-S111.
45. Hricak H. New horizons in genitourinary on cologic imaging. Abclom Imaging 2006;31:182-187.
46. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004;100:2633-2663.
47. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233:701-708.
48. Coakley FV, Chen I, Qayyum A, et al. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int 2007;99:41-43.
49. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223:91-97.
50. Qayyum A, Coakley FV, Lu Y, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004;183:1079-1083.
51. Shukla-Dave A, Hricak H, Eberhardt SC, et al. Chronic prostatitis: MR imaging and
52. 1H MR spectroscopic imaging findings - initial observations. Radiology 2004;231:717-724.
53. Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006;24:825-832.
54. Cunningham CH, Vigneron DB, Marjanska M, et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005;53:1033-1039.
55. Scheenen TW, Gambarota G, Weiland E, et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005;53:1268-1274.
56. Sadi MV, Barrack ER. Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. Cancer Surv 1991;11:195-215.
57. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-488.
58. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004;232:140-146.